No Data
InnoCare Pharma Presents Promising Phase II Data for Psoriasis Drug
INNOCARE (688428.SH): Data on ICP-488 for the treatment of psoriasis was presented as a major oral report at the American Academy of Dermatology (AAD) annual meeting.
INNOCARE (688428.SH) announced that recently, the company will participate in the 2025 American Academy of Dermatology (AAD)...
Atopic Dermatitis: 2025 Pipeline Insights Report Covering 100+ Companies and 120+ Pipeline Drugs, Including ICP-332 (Innocare Pharma), APG777 (Apogee Therapeutics), and Barzolvolimab (Celldex Therapeutics)
GTJA: The Global competitiveness of domestic Innovative Drugs is becoming prominent, and the Operation turning point is approaching.
The current trend in the Innovative Drugs Industry is positive, with continuous marginal improvements. The negotiation time for medical insurance will be advanced in 2025, and the category C directory is expected to be released within the year. It is anticipated that the price drop for biosimilars in the centralized procurement will be moderate. Attention should be paid to recent academic conferences, and there is a bullish outlook on leading Innovative Drug companies.
[Hong Kong Stock Connect] INNOCARE (09969) rises over 9%. The clinical phase II results of orelizumab for treating RRMS show high effectiveness and safety.
Jingwu Financial News | INNOCARE (09969) stock price fluctuates upwards, currently reported at HKD 9.8, an increase of 9.38%, with a trading volume of HKD 0.339 billion. In terms of news, the company announced that its new BTK inhibitor, Orelabrutinib, has shown high efficacy and safety in the Phase II clinical trial for treating relapsing-remitting multiple sclerosis (RRMS). An 80 mg daily dose of Orelabrutinib has been determined for the Phase III clinical trial. At week 12, all three dose groups of Orelabrutinib showed a reduction in cumulative new Gd+T1 lesions in the brain compared to the placebo group.
InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results
